Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs

The ineffectiveness of simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies of strategies for appropriate delivery systems and adjuvants. Biphasic lipid vesicles are formulations suitable for the delivery of proteins, peptides, and oligo/polynucleotides. The purpose of these studies was to investigate the ability of biphasic lipid vesicles (as vaccinetargeting adjuvants) containing a bacterial antigen and unmethylated oligonucleotides containing CGdinucleotides-CpG motifs (CpG ODNs) to induce systemic and mucosal immune responses in pigs. Results showed that while the protein, either alone or with CpG ODNs, did not induce mucosal immune responses, administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in induction of boty systemic and local antibody responses after immunization using a combined mucosal/systemic approach.

[1]  M. Levine,et al.  Mucosally Delivered Salmonella Live Vector Vaccines Elicit Potent Immune Responses against a Foreign Antigen in Neonatal Mice Born to Naive and Immune Mothers , 2004, Infection and Immunity.

[2]  L. Babiuk,et al.  Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. , 2004, Current drug delivery.

[3]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[4]  L. Babiuk,et al.  Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). , 2003, Vaccine.

[5]  D. Kornbrust,et al.  Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications , 2003, Toxicologic pathology.

[6]  M. Baca-Estrada,et al.  Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) , 2002, The Journal of pharmacy and pharmacology.

[7]  P. Payette,et al.  Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. , 2002, FEMS immunology and medical microbiology.

[8]  L. Babiuk,et al.  CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. , 2001, Antisense & nucleic acid drug development.

[9]  R. Weeratna,et al.  The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. , 2001, Vaccine.

[10]  K. Rosenthal,et al.  Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract1 , 2001, The Journal of Immunology.

[11]  A. Krieg,et al.  Immune effects and mechanisms of action of CpG motifs. , 2000, Vaccine.

[12]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[13]  H. Davis,et al.  Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution , 2000, Molecular medicine.

[14]  C. Partidos,et al.  Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants , 2000, Infection and Immunity.

[15]  P. Couvreur,et al.  Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. , 2000, Life sciences.

[16]  K. Beagley,et al.  Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. , 2000, Molecular immunology.

[17]  C. Bennett,et al.  Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. , 2000, The Journal of pharmacology and experimental therapeutics.

[18]  G. Dougan,et al.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.

[19]  H. Davis,et al.  CpG DNA as mucosal adjuvant. , 1999, Vaccine.

[20]  S. Ståhl,et al.  Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. , 1999, Journal of biotechnology.

[21]  M. Murtaugh,et al.  Mucosal immunogenicity and adjuvanticity of cholera toxin in swine. , 1999, Vaccine.

[22]  T. Hirst,et al.  Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. , 1999, Immunology today.

[23]  I. Frazer,et al.  Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. , 1998, Virology.

[24]  C. Alving,et al.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.

[25]  P. Ogra,et al.  Mucosal responses to parenteral and mucosal vaccines. , 1998, Developments in biological standardization.

[26]  M. Marinaro,et al.  Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. , 1996, The Journal of infectious diseases.

[27]  A. Potter,et al.  Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1 , 1993, Infection and immunity.

[28]  J. Mcghee,et al.  The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.

[29]  R. Chanock,et al.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines , 1982, Infection and immunity.